Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682705 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
NCT03682705 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 242 participants.
The verdict
NCT03682705, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
Study Summary
This was a phase 2 study to evaluate the safety and efficacy of elsubrutinib (ELS) and ABBV-599 (ELS plus upadacitinib \[UPA\]) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic drugs (bDMARD)-inadequate response (bDMARD-IR) or bDMARD-intolerant participants with moderately to severely active RA and to define optimal dose for further development.
Interventions
- DRUG Upadacitinib
- DRUG Placebo for upadacitinib
- DRUG Elsubrutinib
- DRUG Placebo for elsubrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2018-10-08 |
| Est. Completion | 2020-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03682705
The ClinicalTrials.gov registry entry for NCT03682705 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Upadacitinib is the first listed.
NCT03682705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03682705 about?
NCT03682705 is a clinical study titled "A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis". This was a phase 2 study to evaluate the safety and efficacy of elsubrutinib (ELS) and ABBV-599 (ELS plus upadacitinib \[UPA\]) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) ...
What is the current status of trial NCT03682705?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2018-10-08. Estimated completion is 2020-03-26.
What interventions are being tested in trial NCT03682705?
The interventions under investigation include: Upadacitinib (DRUG), Placebo for upadacitinib (DRUG), Elsubrutinib (DRUG), Placebo for elsubrutinib (DRUG).
Who is sponsoring clinical trial NCT03682705?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.